Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study
Authors
- Maiyue He (ORCID: https://orcid.org/0000-0001-8389-879X)
- Mingxia Jiang (ORCID: https://orcid.org/0009-0008-6325-4477)
- Hongnan Mo (ORCID: https://orcid.org/0000-0002-2887-7985)
- Bo Lan (ORCID: https://orcid.org/0000-0002-2962-439X)
- Qiao Li (ORCID: https://orcid.org/0000-0002-4547-1266)
- Shanshan Chen (ORCID: https://orcid.org/0000-0001-9723-2403)
- Yiqun Li (ORCID: https://orcid.org/0000-0001-9447-9363)
- Mengqi Zhang (ORCID: https://orcid.org/0000-0003-2090-6320)
- Binghe Xu (ORCID: https://orcid.org/0000-0002-0234-2747)
- Jiaxuan Liu (ORCID: https://orcid.org/0000-0002-7937-320X)
- Shihan Zhou
- Ruigang Cai
- Fei Ma (ORCID: https://orcid.org/0000-0001-8554-7512)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)